Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

Ouch, that hurts, Fibrogen down 83% on pharma test results, no, it won’t bounce

That really is $1.2 billion that has just evaporated with FGEN’s stock price tumble

Update : 27 Jun 2023, 02:02 PM

Fibrogen (NASDAQ: FGEN) stock is down 83% on yesterday. This is not the deflation of some speculative bubble, it is also not a move in some microcap. That really is 83% off a $1.5 billion market capitalisation. $1,2 billion in value that we all thought existed that now does not, the evaporation of that much wealth into the aether. All of which is a markedly good lesson in the dangers of development pharma investing, even as it's not a happy day for FGEN stockholders.

 The specific news is that: “ FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to placebo and did not meet the primary endpoint of change from baseline in forced vital capacity (FVC) at week 48 (p=0.29).” 

 To put that very simply “We tested it, it didn't work”.

 Fibrogen then goes further: “ Based on the results of ZEPHYRUS-1, ZEPHYRUS-2, the second Phase 3 clinical trial, will be discontinued.” And to translate that: “Not only didn't it work, we're not going to try again.”

 Fibrogen stock price from NASDAQ

 There's a lesson to be learned from that stock price chart. The news comes out, FGEN stock drops 80%. There is no serious attempt at a rally over the day, no dead cat bounce. The general assumption in the market is that, well, that's that then.

 The reason why it's so conclusive is twofold. The first is simply the way that drug testing works. Varied levels of it, Phae I, II and so on. This was a Phase III trial. A drug can fail at any stage, but passing a stage just gives the opportunity to spend more money - and the costs rise near exponentially as we rise from I to II to III - on attempting not to fail the next one. The later a drug fails the more it has cost to fail it, that is. So, something that fails at Phase III is a vastly greater expense than something that fails at Phase I. Thus a much greater influence on a stock price of course. 

 The other thing is rather the reverse of that. As a drug passes each stage of testing then some part of the value of it actually succeeding in the end gets baked into the market capitalisation. In theory it should be value of the future profit stream times the probability of it passing all the tests. As we can never calculate the probability this is not accurate but everyone's having their best guess at this. So, a pharma company rises in value when a drug passes Phase I, then again when it passes Phase II and so on. Which makes the crash if it fails at Phase III all the greater. We lose not just the money spent upon development but also the assumed value of it passing tests.

Fibrogen might have other drugs in the pipeline but this sort of failure isn't something that gets reversed.

Top Brokers